SCHEMBL4407535

SCHEMBL4407535

O=C(O)c1csc2c(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.43
MAPK13 O15264 2/20 0.43
MAPK12 P53778 2/20 0.43
MAPK11 Q15759 2/20 0.43
ALOX5 P09917 1/20 0.43
TGFBR1 P36897 1/20 0.43
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
GSK3B P49841 2/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
FGFR1 P11362 1/20 0.40
FRK P42685 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1G2 P78368 1/20 0.40
PRKCD Q05655 1/20 0.40
ERBB4 Q15303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410066 0.86 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4408131 0.82 MAPK14 (0.46) MAPK14ALDH1A1GAAMAPK10ROCK1
SCHEMBL4408109 0.80 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4417408 0.77 MAPK14 (0.41) MAPK14MAPK13MAPK12MAPK11GSK3B
SCHEMBL4410117 0.72 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4411014 0.68 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4410497 0.68 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL25637543 0.67 PARP1 (0.48) MAPK13ALDH1A1PRKD3MAP4K4CSNK1D
SCHEMBL4408115 0.67 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL22245585 0.66 KDM4E (0.48) MAPK14MAPK13MAPK12MAPK11ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP disclosed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK13 39/4885MAPK12 41/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK13 39/4885MAPK12 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.